|
| Press Releases |
|
 |
|
| Thursday, March 7, 2024 |
|
|
Lexaria Awards Contract For Next GLP-1 Human Pilot Study |
| Lexaria Bioscience Corp. (Nasdaq: LEXX) (Nasdaq: LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces it has hired a contract research organization ("CRO") to perform the Company's second DehydraTECH-powered glucagon-like peptide 1 ("GLP-1") human pilot study #2 (the "Study"). more info >> |
|
| Tuesday, March 5, 2024 |
|
|
Lexaria to Begin Diabetes and Weight Loss Animal Study WEIGHT-A24-1 |
| more info >> |
|
| Monday, March 4, 2024 |
|
|
7% Weight Loss in Animals Supports Lexaria's Next 8-week Animal Study |
| more info >> |
|
| Friday, March 1, 2024 |
|
|
Lexaria Announces FDA Clearance for its Planned U.S. Phase 1b Hypertension Clinical Trial |
| Lexaria Bioscience Corp. (Nasdaq: LEXX; LEXXW), a global innovator in drug delivery platforms, announces that the U.S. Food and Drug Administration (FDA) has confirmed effectiveness as of February 28, 2024 of the Company's investigational new drug (IND) application thereby cleared for Lexaria to conduct its planned U.S. Phase 1b hypertension clinical trial HYPER-H23-1 utilizing DehydraTECH-CBD. more info >> |
|
| Saturday, February 17, 2024 |
|
|
Lexaria Announces Closing of $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules |
| more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
珠宝双展匯聚逾82,000环球买家
Mar 9, 2025 13:51 HKT/SGT
|
|
|
珠寶雙展匯聚逾82,000環球買家
Mar 9, 2025 13:41 HKT/SGT
|
|
|
Twin jewellery shows attract over 82,000 global buyers
Mar 9, 2025 13:19 HKT/SGT
|
|
|
OrbusNeich Achieves Fourth Consecutive Year of Revenue Growth with Record High Revenue of US$164.1 Million and Net Profit of US$39.7 Million
Mar 8, 2025 19:40 HKT/SGT
|
|
|
Everest Medicines Hits Three-Year High as AI+mRNA Pipeline Reshapes Valuation
Mar 8, 2025 19:20 HKT/SGT
|
|
|
uSMART Securities Initiates Coverage on NAAS Technology with a 'Buy' Rating and a Target Price of US$3.2 per ADS, Citing Industry Leadership and Profitability Outlook
Mar 7, 2025 21:26: JST
|
|
|
Everest Medicines Hits Three-Year High as AI+mRNA Pipeline Reshapes Valuation
Mar 7, 2025 20:31: JST
|
|
|
uSMART Securities Initiates Coverage on NAAS Technology with a 'Buy' Rating and a Target Price of US$3.2 per ADS, Citing Industry Leadership and Profitability Outlook
Mar 7, 2025 20:26 HKT/SGT
|
|
|
雲頂新耀股價創3年新高 AI+mRNA賦能管線重塑估值
Mar 7, 2025 19:24 HKT/SGT
|
|
|
云顶新耀股价创3年新高 AI+mRNA赋能管线重塑估值
Mar 7, 2025 19:16 HKT/SGT
|
|
|
業聚醫療連續四年實現收入增長 達1.64億美元創新高 純利達3,970萬美元 建議派發末期股息每股10港仙
Mar 7, 2025 18:28 HKT/SGT
|
|
|
业聚医疗连续四年实现收入增长 达1.64亿美元创新高 纯利达3,970万美元 建议派发末期股息每股10港仙
Mar 7, 2025 18:10 HKT/SGT
|
|
|
東信營銷科技：中國AI營銷龍頭斬獲多模態雙備案 技術實力獲國家級認證
Mar 7, 2025 17:58 HKT/SGT
|
|
|
东信营销科技：中国AI营销龙头斩获多模态双备案 技术实力获国家级认证
Mar 7, 2025 17:20 HKT/SGT
|
|
|
Japan's Telecommunications Carriers Enhance Disaster Response with On-site Training for Joint Use of Marine Vessels
Mar 7, 2025 16:24 JST
|
|
|
|
|
More News >> |
|
|
|
|
|
